|Original language||English (US)|
|Number of pages||2|
|Journal||JAMA - Journal of the American Medical Association|
|State||Published - Nov 5 2019|
Bibliographical noteFunding Information:
reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Kelly reported serving as an unpaid advisor to Novo Nordisk, Vivus, Orexigen, Takeda, and WW [Weight Watchers] and receiving research support from AstraZeneca for an NIH-funded clinical trial. Dr Jastreboff reported receiving personal fees from and serving as a consultant for Novo Nordisk and Medtronic Diabetes and receiving personal fees from Rhythm Pharmaceuticals.